Cisplatin/Etoposide and Concurrent Radiotherapy With or Without Celecoxib in Patients With Unresectable Locally Advanced Non-small Cell Lung Cancer (NSCLC)

Inclusion Criteria:

* • 18-70 years old, male or female

  * Histological or cytological evidence of NSCLC.
  * Unresectable Stage III NSCLC.
  * Karnofsky score: at least 70.
  * Estimated survival: at least 6 months
  * Not receiving radiotherapy or combined modality therapy to treat another malignancy.
  * No history of active gastric ulcer, active GI bleeding, or renal failure.
  * No severe hypertension, cardiac disease, or diabetes mellitus
  * Normal blood routine and chemical tests
  * Patients or guardian must be informed of the investigational nature of this study and must sign and give written informed consent in accordance with institutional and federal guidelines.

Exclusion Criteria:

* • Other malignancies simultaneously except in situ cervix or non-melanoma skin cancer

  * Extensive distant metastases
  * Pregnancy or in lactation
  * Allergic to Sulfonamides, NSAIDS or Celebrex
  * Routine use of NSAIDS such as high dose of Aspirin
  * History of cardiovascular diseases including: myocardial infraction, angina, coronary angioplasty, congestive heart failure, stroke, or coronary bypass surgery in the last 6 months.
  * Abnormal coagulation or history of deep venous thrombosis, pulmonary embolism, systemic lupus erythematous, family history of protein S or C deficiencies, prior heparin-induced thrombocytopenia, Factor V Leiden deficiencies or high homocysteine levels.